Literature DB >> 12472767

Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.

Iris Feria1, Israel Pichardo, Patricia Juárez, Victoria Ramírez, Marco A González, Norma Uribe, Romeo García-Torres, Fernando López-Casillas, Gerardo Gamba, Norma A Bobadilla.   

Abstract

BACKGROUND: Cyclosporine A (CsA) is an immunosuppressive drug used to prevent tissue allograft rejection. However, its long-term utilization is limited due to chronic nephrotoxicity for which no prevention is available. This study evaluated the effect of spironolactone on renal functional and structural alterations induced by CsA, and assessed whether the protective effect was associated with a reduction of transforming growth factor-beta (TGF-beta) and the change of extracellular matrix protein mRNA level.
METHODS: Male Wistar rats fed with low sodium diet were divided in four treatment groups: vehicle, CsA (30 mg/kg), spironolactone (20 mg/kg), or CsA+spironolactone. After 21 days, creatinine clearance (CCr), blood CsA, arteriolopathy in renal tissue, and TGF-beta, collagen I, collagen IV, fibronectin, and epidermal growth factor (EGF) mRNA levels in renal cortex were determined.
RESULTS: CsA reduced the CCr and up-regulated TGF-beta, collagen I and fibronectin mRNA expression with a significant development of arteriolopathy, and reduced EGF mRNA levels. In contrast, spironolactone administration prevented the fall in renal function and TGF-beta, collagen I, and fibronectin up-regulation, together with a reduction of arteriolopathy and tubulointerstitial fibrosis.
CONCLUSION: Our data show that aldosterone plays an important role as a mediator of renal injury induced by CsA. Thus, mineralocorticoid receptor blockade may be a potential strategy to prevent CsA nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12472767     DOI: 10.1046/j.1523-1755.2003.00707.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

1.  Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration.

Authors:  Cristian A Amador; Jean-Philippe Bertocchio; Gwennan Andre-Gregoire; Sandrine Placier; Jean-Paul Duong Van Huyen; Soumaya El Moghrabi; Stefan Berger; David G Warnock; Christos Chatziantoniou; Iris Z Jaffe; Philippe Rieu; Frederic Jaisser
Journal:  Kidney Int       Date:  2016-02       Impact factor: 10.612

Review 2.  Aldosterone and diabetic kidney disease.

Authors:  Young Sun Kang; Dae Ryong Cha
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

3.  Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy.

Authors:  Mara Medeiros; Luis Velásquez-Jones; Ana M Hernández; Guillermo Ramón-García; Saúl Valverde; Yolanda Fuentes; Arindal Vargas; Mauricio Patiño; Rosalba Pérez-Villalva; Juan Antonio Ortega-Trejo; Jonatan Barrera-Chimal; Norma A Bobadilla
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-23       Impact factor: 8.237

4.  Upregulation and intrarenal redistribution of heat shock proteins 90alpha and 90beta by low-sodium diet in the rat.

Authors:  Victoria Ramírez; Norma Uribe; Romeo García-Torres; Clementina Castro; Julieta Rubio; Gerardo Gamba; Norma A Bobadilla
Journal:  Cell Stress Chaperones       Date:  2004       Impact factor: 3.667

5.  Renoprotective mechanisms of soy protein intake in the obese Zucker rat.

Authors:  Joyce Trujillo; Cristino Cruz; Armando Tovar; Vishal Vaidya; Elena Zambrano; Joseph V Bonventre; Gerardo Gamba; Nimbe Torres; Norma A Bobadilla
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-24

6.  Aldosterone-receptor antagonism and end-stage renal disease.

Authors:  Niall McLaughlin; Todd W B Gehr; Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

7.  Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.

Authors:  Jiang Tian; Amjad Shidyak; Sankaridrug M Periyasamy; Steven Haller; Mohamed Taleb; Nasser El-Okdi; Jihad Elkareh; Shalini Gupta; Sabry Gohara; Olga V Fedorova; Christopher J Cooper; Zijian Xie; Deepak Malhotra; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

8.  Spironolactone rescues Dot1a-Af9-mediated repression of endothelin-1 and improves kidney injury in streptozotocin-induced diabetic rats.

Authors:  Qiaoling Zhou; Kanghan Liu; Hongyu Wu; Lihe Chen; Veeraragoo Pouranan; Mingxia Yuan; Zhou Xiao; Weisheng Peng; Ao Xiang; Rong Tang; Wenzheng Zhang
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

9.  The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity.

Authors:  Finn Thomsen Nielsen; Boye L Jensen; Pernille B L Hansen; Niels Marcussen; Peter Bie
Journal:  BMC Nephrol       Date:  2013-02-20       Impact factor: 2.388

10.  Aldosterone-induced TGF-beta1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells.

Authors:  Jeong-Sun Han; Bum-Soon Choi; Chul-Woo Yang; Yong-Soo Kim
Journal:  J Korean Med Sci       Date:  2009-01-28       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.